Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Candel Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Candel Therapeutics, Inc.’s stock price such as:

• Candel Therapeutics, Inc.’s current stock price and volume
• Why Candel Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CADL from analysts
• CADL’s stock price momentum as measured by its relative strength

About Candel Therapeutics, Inc. (CADL)

Before we jump into Candel Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Want to learn more about Candel Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Candel Therapeutics, Inc..

Candel Therapeutics, Inc.’s Stock Price as of Market Close

As of May 14, 2026, 9:46 AM, CST, Candel Therapeutics, Inc.’s stock price was $8.650.

Candel Therapeutics, Inc. is down 3.24% from its previous closing price of $8.940.

During the last market session, Candel Therapeutics, Inc.’s stock traded between $8.270 and $9.270. Currently, there are approximately 54.90 million shares outstanding for Candel Therapeutics, Inc..

Candel Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Candel Therapeutics, Inc. Stock Price History

Candel Therapeutics, Inc.’s (CADL) price is currently up 39.97% so far this month.

During the month of May, Candel Therapeutics, Inc.’s stock price has reached a high of $9.270 and a low of $6.110.

Over the last year, Candel Therapeutics, Inc. has hit prices as high as $9.255 and as low as $4.350. Year to date, Candel Therapeutics, Inc.’s stock is up 53.1%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Candel Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 13, 2026, there were 2 analysts who downgraded Candel Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Candel Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Candel Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Candel Therapeutics, Inc. (CADL) by visiting AAII Stock Evaluator.

Relative Price Strength of Candel Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 13, 2026, Candel Therapeutics, Inc. has a weighted four-quarter relative price strength of 17.38%, which translates to a Momentum Score of 88 and is considered to be Very Strong.

Want to learn more about how Candel Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Candel Therapeutics, Inc. Stock Price: Bottom Line

As of May 14, 2026, Candel Therapeutics, Inc.’s stock price is $8.650, which is down 3.24% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Candel Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.